People ask Foley from time to time about which are the top nanotechnology patents. Good question. Does that mean the most valuable patents now or the potentially most valuable
patents in ten years? Does it mean the most technologically interesting patents? Sadly, some really nifty patents are not very commercially important, and some very pedestrian patents are
commercial gold mines. Here, we provide one brief, highly subjective, and speculative commentary about a dozen or so nanotechnology patents which struck us as either important,
interesting, or in some cases, BOTH.
Read the complete article by clicking the link below.
patents in ten years? Does it mean the most technologically interesting patents? Sadly, some really nifty patents are not very commercially important, and some very pedestrian patents are
commercial gold mines. Here, we provide one brief, highly subjective, and speculative commentary about a dozen or so nanotechnology patents which struck us as either important,
interesting, or in some cases, BOTH.
Read the complete article by clicking the link below.
Related Insights
June 6, 2025
Energy Current
House Bill 3809 Adds Obligations to Battery Energy Storage Lessees in Texas
On May 29, 2025, House Bill No. 3809 was signed into law by Texas Governor Greg Abbott. Born out of a crop of bills regulating renewable…
June 23, 2025
Events
Third Annual Transaction Solutions Symposium
Foley & Lardner is sponsoring the Third Annual Transaction Solutions Symposium — a premier conference focused on de-risking strategies that enhance deal execution and business outcomes. Rishi Sodhi will be speaking as part of the Tax Liability Insurance: Current Trends, Controversies and Claims panel.
June 5, 2025
Health Care Law Today
GLP-1 Compounded Medications Targeted by Connecticut Attorney General
On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications.